FDA approves Tecentriq plus chemo for ES-SCLC
May 2019—Genentech announced FDA approval of Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the initial treatment of adults with extensive-stage small cell lung cancer.
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2019—Genentech announced FDA approval of Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the initial treatment of adults with extensive-stage small cell lung cancer.
May 2019—Cepheid announced the CE-IVD marking of Xpert HBV Viral Load, a rapid test for the quantitation of hepatitis B virus that delivers results in less than one hour.
May 2019—Binding Site’s Immunologicals Group has added purified monoclonal antibodies for the testing of human immunodeficiency virus, designed for use as components within enzyme immunoassay test procedures.
May 2019—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC.
May 2019—Nikon Instruments debuted the OS-15-N, a digital slide scanning system featuring Nikon optics, at the USCAP annual meeting, March 16–21, National Harbor, Md. Nikon partnered with OptraScan to provide an end-to-end digital pathology solution that takes advantage of Nikon’s optics and OptraScan’s desktop slide scanning system, the OS-15.
May 2019—Agilent Technologies announced its Magnis NGS Prep System, a fully automated next-generation sequencing library preparation system designed to run complex DNA sequencing assays.
May 2019—Helmer Scientific has unveiled its GX Solutions, professional medical-grade refrigerators with OptiCool cooling systems. The refrigerators have been designed for the needs of critical health care applications, such as medication, vaccine, blood, and patient sample storage and offer control in temperature management, noise management, and energy management.
May 2019—Roche and Spark Therapeutics entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics for about $4.3 billion.
May 2018—Sysmex America announced the availability of its first fully automated urine particle counter and digital imaging system, the UN-2000. The scalable system is composed of the UF-5000 automated urine particle analyzer and UD-10 automated urine particle digital imaging device.
May 2019—Sakura Finetek USA launched two ready-to-use antibodies in the United States and eight outside the U.S. for use on the Tissue-Tek Genie Advanced Staining System.